Allopurinol for Gout: How It Works and What to Expect

Picture a tap that has been left running. Nearly every other gout medicine hands you a mop. Colchicine, ibuprofen, a steroid injection: all of them clean up the flare after the floor is already soaked, and all of them are worth having. Allopurinol does something quieter. It reaches back and turns the tap down.

Your body makes uric acid at the end of a production line, and the last worker on that line is an enzyme called xanthine oxidase. Allopurinol blocks it, which is why it belongs to a class called xanthine oxidase inhibitors¹. Less enzyme activity means less uric acid made, which means less of it to crystallise in a joint at three in the morning. The NHS says it plainly: allopurinol is a medicine used to lower levels of uric acid in your blood, and taken regularly it can lower the number of gout attacks and help prevent damage to the joints².

Here is the part nobody prepares you for: you will not feel it working. There is no rush of relief, no moment where something clicks into place. The good news arrives as an absence. Flares that simply stop turning up, so gradually that you may not notice until you realise you have gone a whole season without thinking about your foot.

Something worth saying out loud, because the rest of the internet has spent decades saying the opposite. You did not eat your way into this. When researchers pooled population cohorts and asked how much of the uric acid in your blood your diet actually explains, each dietary pattern they tested accounted for no more than about 0.3% of the variation, while common genetic variation accounted for 23.9%³. Your kidneys set the level of the tap, and you did not choose your kidneys. The beer was just standing nearby. Allopurinol works on the tap, which is the whole reason it works at all.

Allopurinol is not really prescribed to treat gout. It is prescribed to hit a number.

For everyone taking urate-lowering therapy, the American College of Rheumatology strongly recommends continuing it to reach and hold a serum urate below 6 mg/dL⁴. NICE sets out the same target in UK units: below 360 micromol per litre, and lower still, below 300, for people with tophi or chronic gouty arthritis⁵. Two health systems, one line in the sand.

There is an older way of thinking that says medicate the flare, leave the uric acid alone, and get on with your life. We think it is out of date, and we think it is part of why so many people spend years being told their gout is managed while their joints quietly take damage in the months between flares. The pain is the smoke. The uric acid is the fire.

The guideline saves its strongest language for the people with the most to lose: it recommends starting urate-lowering therapy for anyone with tophaceous gout, joint damage visible on imaging, or frequent flares⁴. Of the options available, the ACR names allopurinol the preferred first-line choice, including for people with moderate to severe chronic kidney disease⁴. NICE takes a slightly different line and offers allopurinol or febuxostat as equal first-line starts⁵. That disagreement between two serious bodies is real, and it is a perfectly fair thing to ask your clinician about.

There is no standard allopurinol dose. The dose that works is whatever gets you under 6 and keeps you there, and nobody can know that in advance, including your doctor.

So it is started small. The ACR describes a low starting dose, at or below 100 mg a day and lower than that in chronic kidney disease, then titrating upward from there⁴. NICE describes the same rhythm from the other side of the Atlantic: start with a low dose, then use monthly serum urate levels to guide dose increases, as tolerated, until the target is reached⁵.

That slow climb is doing real work. It gives your clinician two things to watch at once, the number in your blood and how you are tolerating the medicine, and it keeps the whole thing adjustable. Some people land at target on a modest dose. Others need considerably more. Neither fact says anything about your character.

Which makes the blood test the centre of everything here. You cannot feel uric acid. You can only measure it, and a number you never see cannot guide a decision. Ask for the figure itself rather than a reassuring adjective, and write it down. A reading of 6.4 and a reading of 5.2 are two different futures, and only one of them is dissolving crystals.

This is the part that makes people quit, and it usually happens around week three.

You start a medicine to stop flares, and you get a flare. Then perhaps another. It feels like proof that the drug does not work, or that your body is rejecting it, and it is neither. As uric acid falls, crystals that have been sitting quietly in the joint can start to break up, and your immune system, which has never liked them, notices the debris. The flare is not the disease winning. It is the backlog clearing.

The guidelines treat this as expected rather than exceptional, which is why starting urate-lowering therapy comes paired with an anti-inflammatory to cover the transition. The ACR strongly recommends continuing that cover for 3 to 6 months rather than less than 3, with ongoing evaluation and more cover if flares keep coming⁶. NICE names colchicine first for the job, with a low-dose NSAID or a low-dose oral corticosteroid if colchicine is not suitable⁵.

If nobody offered you that cover, it is worth asking why. Not every prescription arrives with the explanation attached, and a lot of people abandon allopurinol in month two believing it failed them, when what actually happened is that they were handed the right medicine without the bridge that was supposed to come with it.

On timing: the NHS says you will usually start allopurinol after an acute attack has completely settled², though practice varies and some clinicians will start during one. Staying on it through a flare once you are established is a different question, and the answer there has changed. See the FAQ below.

There is one rare thing allopurinol can do, and one test that helps flag who is most at risk of it.

A small number of people have a severe hypersensitivity reaction to the drug. It is uncommon, and most people take allopurinol for decades without anything of the sort. It is also serious enough to be worth two minutes of your attention now instead of a bad surprise in week five.

The ACR conditionally recommends testing for a gene variant called HLA-B*5801 before starting allopurinol in patients of Southeast Asian descent, which the guideline spells out as Han Chinese, Korean and Thai, and in African American patients. For everyone else, it conditionally recommends against testing⁶. The recommendation is targeted rather than universal, which is the guideline's careful way of saying this risk is not distributed evenly.

If you are in one of those groups and nobody has mentioned it, raise it. It does not need to be a confrontation. "Should I be tested for HLA-B*5801 first?" is enough, and most clinicians will know exactly what you mean.

Allopurinol is not a course you finish. It is a long arrangement.

It works while you take it, and only while you take it. Stop, and the tap opens again, and your uric acid drifts back to whatever level your biology prefers, usually without any warning at all until the night it announces itself. The ACR's position is to continue urate-lowering therapy to achieve and maintain the target⁴, and maintain is the load-bearing word in that sentence.

If you have kidney disease, this is where allopurinol earns its reputation. The ACR names it the preferred first-line urate-lowering therapy including for moderate to severe chronic kidney disease⁴, and once kidney function is meaningfully reduced, at stage 3 or beyond, the guideline strongly prefers a xanthine oxidase inhibitor over the uricosuric alternative⁶. The starting dose is lower⁴ and the climb is slower, but the door is not closed to you.

The reward for all this is dull, and the dullness is the point. Taken regularly, allopurinol can lower the number of gout attacks and help prevent damage to the joints². There will be no moment of triumph, no finish line to cross. What you get instead is an ordinary Tuesday where your foot is just a foot, and then another one, and then a year of them.